Institutional Support from ACCIÓ
HIGIA Health Solutions has received continuous institutional support from ACCIÓ – the Agency for Business Competitiveness of the Government of Catalonia, recognizing the company’s technological innovation capacity and its contribution to the development of advanced Artificial Intelligence solutions for healthcare.
Startup Capital Grant (2023) – Predictive Models for Cardiometabolic Diseases
In 2023, HIGIA was awarded the Startup Capital grant to develop Artificial Intelligence predictive models for major cardiometabolic diseases, including Type 2 Diabetes, chronic kidney disease (CKD), hypertension, dyslipidemia, obesity, metabolic-associated fatty liver disease (MASLD/NASH), atherosclerosis, atrial fibrillation, cardiomyopathy, cerebrovascular disease, heart failure, and ischemic heart disease, enabling early risk stratification and preventive healthcare strategies.
PREGEMACIA Project (2025) – AI Platform for Personalized Cardiometabolic Management
In 2025, HIGIA received funding for the PREGEMACIA project, focused on the development of an interoperable AI-based platform for the prediction and personalized management of cardiometabolic diseases. The project integrates multimodal predictive models together with synthetic clinical data generation technologies, enabling patient journey simulation, explainable analytics, and decision-support capabilities at both patient and population levels.
European R&D Project Vouchers (2025) – European Innovation Acceleration
Also in 2025, HIGIA received support through the ACCIÓ European R&D Project Vouchers, enabling preparation for participation in the European Innovation Council (EIC) Pathfinder Challenge under Horizon Europe, within the call focused on Generative AI technologies for cancer diagnosis and treatment.